Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Hims & Hers Health Earnings Call: Key Takeaways

HIMS reported 49% revenue growth but saw a sequential subscriber decline of 100,000, pivoting toward higher-margin branded assortments and international expansion while investing heavily in AI and supply chain infrastructure.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthDomestic grew 21% to $657M; International grew 4x to $233M.
Mgmt ConfidenceHigh confidence in long-term arc despite near-term subscriber and margin volatility.
Demand VisibilityRecord first-half additions; record interest in Wegovy pill and Lily partnership.
Margin TrendsGross margins fell 7 points to 57% due to lower-margin branded products.
Op. LeverageMarketing improved 7 points to 28% of revenue; G&A improved 5 points.
Pricing PowerStrategic pricing initiatives in UK/Germany; passing efficiencies back as lower prices.
Vol vs PriceGrowth driven by higher price-point branded offerings despite sequential subscriber decline.
Segment GrowthHers approaching $1B; Testosterone reaching $100M run rate; International scaling rapidly.
New ClientsPartnerships with Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) expanded assortment.
Capex & Debt$710M cash/investments; $26M free cash flow; Eucalyptus acquisition integration complete.
RegulatoryMonitoring FDA/HHS peptide rulings for BPC 157 and TB 500 launches.
CommentaryPrioritizing long-term platform value and customer relationships over near-term subscriber metrics.
New LaunchesInjectable TRT launched; Peptides Plus (Sermorelin, NAD+) launching end of month.

Growth

Revenue grew 49% year-over-year to $890 million; International revenue more than 4x to $233 million.

Outlook

Tightened 2026 revenue guidance to $3.13-$3.15 billion; International run rate $1 billion by 2027.

Risks

Sequential decline of 100,000 subscribers and 7-point gross margin drop to 57% due to mix shift.

Source

The company's earnings call, NYSE: HIMS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Hims & Hers Health, Inc.: key numbers

Share price
$18.56Close, Nov 16
Sector
Industrial Applications and Services
Industry
Services-Offices & Clinics of Doctors of MedicineSIC 8011

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Hims & Hers Health, Inc.

All →
4:18 PM ET 10-Q
Financial Results ▶ Call

Hims & Hers Health Q3 2026 Results: Net Loss of $33M

Hims & Hers Health, Inc. reported a net loss of $33.0 million for the third quarter of 2026, a significant decline from a net income of $15.8 million in the prior year period, despite revenue growing to $890.4 million. The company's balance sheet shows a substantial increase in goodwill and intangible assets, reflecting significant acquisition activity during the first nine months of the year.

Key figure
Net loss $33M
4:13 PM ET 8-K
Leadership Change

Hims & Hers Health Leadership Change

Hims & Hers Health, Inc. increased its board size to ten and appointed Dr. Andrew Huberman as a director, effective November 4, 2026. Alongside his board role, Dr. Huberman entered into a brand marketing and advisory agreement worth $3.5 million annually, while his media company, Scicomm Media LLC, secured a $5 million annual podcast advertising contract.

Counterparty
Dr. Andrew Huberman
Term
through 2027 annual meeting
4:12 PM ET 8-K
Financial Results

Hims & Hers Health Financial Results

Hims & Hers Health reported Q3 2026 revenue of $890.4 million, a 49% year-over-year increase driven by significant international growth and a 13% rise in subscribers to 2.8 million. The company reported a net loss of $33.0 million compared to a profit in the prior year, while tightening its full-year revenue guidance and reducing its Adjusted EBITDA outlook.

Term
Q3 2026

“In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.”

Andrew Dudum, co-founder and CEO

“In the third quarter, we continued to apply what we’ve learned to make deliberate strategic decisions to position Hims & Hers for durable, multi-year growth.”

Yemi Okupe, Chief Financial Officer
4:12 PM ET Form 4
Insider Selling

Hims & Hers Health CLO Soleil Boughton Sells $95.6K of Stock

Soleil Boughton, CLO, sold 3,462 shares of Hims & Hers Health, Inc. at $27.60 a share, worth $95.6K in total on Oct 28, 2026. Shares held after the trade: 293,886 (-1.2%).

Value
$95.6K
Shares
3,462
Price
$27.60
Role
CLO
Holding change
-1.2%
Trade date
Oct 28, 2026
4:45 PM ET Form 4
Insider Selling

Hims & Hers Health CLO Soleil Boughton Sells $101K of Stock

Soleil Boughton, CLO, sold 3,461 shares of Hims & Hers Health, Inc. at $29.06 a share, worth $101K in total on Oct 14, 2026. Shares held after the trade: 297,348 (-1.2%).

Value
$101K
Shares
3,461
Price
$29.06
Role
CLO
Holding change
-1.2%
Trade date
Oct 14, 2026
4:14 PM ET 8-K
Executive Compensation

Hims & Hers Health Executive Compensation

Hims & Hers Health, Inc. appointed Jonathan M. Franklin as Chief Accounting Officer and Principal Accounting Officer, effective October 9, 2026. Mr. Franklin's compensation package includes a $425,000 base salary, a $150,000 signing bonus, and $3,000,000 in restricted stock units. He succeeds Irene Becklund, who is transitioning to an advisory role through July 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.